Climb Bio, Inc. CLYM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $38.76M-17.0% | $46.71M+20.0% | $38.93M+7.8% | $36.1M+18.1% | $30.57M+113% | ||
| $21.32M+0.7% | $21.17M+2.9% | $20.56M+1.6% | $20.24M+2.2% | $19.8M+23.6% | ||
| $60.08M-11.5% | $67.88M+14.1% | $59.5M+5.6% | $56.34M-44.8% | $102.03M+24.4% | ||
| -$60.08M+11.5% | -$67.88M-14.1% | -$59.5M-5.6% | -$56.34M+44.8% | -$102.03M-24.4% | ||
| $7.28M-9.3% | $8.03M-8.2% | $8.75M-8.7% | $9.58M+5.8% | $9.05M+11.4% | ||
| -$52.79M+11.8% | -$59.85M-17.9% | -$50.75M-8.5% | -$46.76M+49.7% | -$92.98M-25.8% | ||
| -$0.77+12.5% | -$0.88— | —— | —— | —— | ||
| -$59.94M+11.6% | -$67.79M-14.1% | -$59.43M-5.6% | -$56.3M— | —— | ||
| -$60.08M+11.5% | -$67.88M-14.1% | -$59.5M-5.6% | -$56.34M+44.8% | -$102.03M-24.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Climb Bio, Inc. profitable?
- Climb Bio, Inc. is not currently profitable: it reported a net loss of $52.8M over the trailing twelve months.
- What is Climb Bio, Inc.'s earnings per share?
- Climb Bio, Inc.'s diluted EPS over the trailing twelve months is $-0.77.
- Where does Climb Bio, Inc.'s income statement data come from?
- Every line is extracted from Climb Bio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.